Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

Alongside the approval of Ponlimsi, the FDA is reviewing a BLA for TEV-45779, a biosimilar candidate for Xolair, covering all currently approved indications.

Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability ...

Many women on dialysis quickly developed severe hypocalcemia after starting denosumab (Prolia) for osteoporosis, Medicare data showed. During the first 12 weeks of treatment, 41.1% of women on ...

Treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs failed to mitigate bone mineral density ...

Osteoporosis is a degenerative, debilitating bone disease that is increasingly prevalent in postmenopausal women. Despite its being classified as one of the four most dangerous health issues today, a ...

REYKJAVIK, ICELAND (July 20, 2022) – Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today ...

REYKJAVIK, Iceland, July 02, 2024 (GLOBE NEWSWIRE) -- Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today ...